Bausch + Lomb Overview

  • Year Founded
  • 1852

Year Founded

  • Status
  • Public

  • Employees
  • 13,000

Employees

  • Stock Symbol
  • BLCO

Stock Symbol

  • Investments
  • 39

  • Share Price
  • $19.30
  • (As of Friday Closing)

Bausch + Lomb General Information

Description

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes brands like Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, and surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xiidra and Miebo that treat various eye complications.

Contact Information

Website
www.bausch.com
Formerly Known As
Wp Prism, Bausch & Lomb Optical Company
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Corporate Office
  • 400 Somerset Corporate Boulevard
  • Bridgewater, NJ 08807
  • United States
+1 (866)
Primary Industry
Therapeutic Devices
Other Industries
Surgical Devices
Pharmaceuticals
Stock Exchange
TSE
Corporate Office
  • 400 Somerset Corporate Boulevard
  • Bridgewater, NJ 08807
  • United States
+1 (866)

Bausch + Lomb Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Bausch + Lomb Stock Performance

As of 20-Nov-2026, Bausch + Lomb’s stock price is $19.30. Its current market cap is $6.9B with 357M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$19.30 $20.72 $14.57 - $21.50 $6.9B 357M 2.53K -$0.31

Bausch + Lomb Financials Summary

As of 30-Sep-2026, Bausch + Lomb has a trailing 12-month revenue of $5.42B.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 10,945,391 10,851,234 10,485,789 10,300,418
Revenue 5,418,000 5,101,000 4,791,000 4,146,000
EBITDA 770,000 513,000 586,000 484,000
Net Income (111,000) (360,000) (317,000) (260,000)
Total Assets 13,959,000 14,022,000 13,469,000 13,442,000
Total Debt 5,095,000 5,082,000 4,784,000 4,562,000
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Bausch + Lomb Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Bausch + Lomb‘s full profile, request access.

Request a free trial

Bausch + Lomb Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent c
Therapeutic Devices
Bridgewater, NJ
13,000 As of 2025

Geneva, Switzerland
 

San Ramon, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Bausch + Lomb Competitors (8)

One of Bausch + Lomb’s 8 competitors is Alcon, a Corporate Backed or Acquired company based in Geneva, Switzerland.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Alcon Corporate Backed or Acquired Geneva, Switzerland
The Cooper Companies Corporation San Ramon, CA
Staar Surgical Corporation Lake Forest, CA
RxSight Formerly VC-backed Aliso Viejo, CA
Novo Nordisk Corporation Bagsvaerd, Denmark
You’re viewing 5 of 8 competitors. Get the full list »

Bausch + Lomb Patents

Bausch + Lomb Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-11878479-B1 Film winding assembly and winding method for use in fiber-reinforced plastic tank production Active 20-Sep-2022
US-D921212-S1 Light therapy device Active 09-Jan-2020
US-D922595-S1 Light therapy device Active 09-Jan-2020
US-20200375681-A1 Detachable finger-activated surgical control device Inactive 03-Jun-2019
WO-2020247340-A1 Detachable finger-activated surgical control device Inactive 03-Jun-2019 A61B17/00
To view Bausch + Lomb’s complete patent history, request access »

Bausch + Lomb Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Bausch + Lomb Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Bausch + Lomb‘s full profile, request access.

Request a free trial

Bausch + Lomb Investments & Acquisitions (39)

Bausch + Lomb’s most recent deal was a Corporate with Emmecell. The deal was made on 16-Jun-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Emmecell 16-Jun-2026 Corporate Drug Discovery
Precilens 15-Jun-2026 Merger/Acquisition Therapeutic Devices
Character Biosciences 02-Sep-2025 Later Stage VC Drug Discovery
Whitecap Biosciences 03-Jan-2025 Merger/Acquisition Drug Discovery
ELIOS Vision 10-Dec-2024 Merger/Acquisition Surgical Devices
You’re viewing 5 of 39 investments and acquisitions. Get the full list »

Bausch + Lomb ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

20.05 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Healthcare

Industry

of 590

Rank

Percentile

Medical Supplies

Subindustry

of 60

Rank

Percentile

To view Bausch + Lomb’s complete esg history, request access »

Bausch + Lomb Exits (5)

Bausch + Lomb’s most recent exit was on 01-Jan-2015 from Checkedup. The exit was categorized as with 2 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Checkedup 01-Jan-2015 Completed
  • 2 buyers
Cutting Edge Manufacturing 01-Jan-2000 Completed
Miracle-Ear 01-Jan-1993 Completed
Charles River Laboratories International 01-Jan-1984 Completed
Minnesota Eye Consultants Corporate Completed
To view Bausch + Lomb’s complete exits history, request access »

Bausch + Lomb Affiliates

Subsidiaries (6)

Name Industry Location Year Founded
ELIOS Vision Los Angeles, CA 2019
Trukera Medical Southlake, TX 1996
Total Titanium Red Bud, IL 1983
Precilens Créteil, France 1981
Laboratorio Pförtner Cornealent Buenos Aires, Argentina 1943
You’re viewing 5 of 6 affiliates. Get the full list.  »

Bausch + Lomb FAQs

  • When was Bausch + Lomb founded?

    Bausch + Lomb was founded in 1852.

  • Where is Bausch + Lomb headquartered?

    Bausch + Lomb is headquartered in Bridgewater, NJ.

  • What is the size of Bausch + Lomb?

    Bausch + Lomb has 13,000 total employees.

  • What industry is Bausch + Lomb in?

    Bausch + Lomb’s primary industry is Therapeutic Devices.

  • Is Bausch + Lomb a private or public company?

    Bausch + Lomb is a Public company.

  • What is Bausch + Lomb’s stock symbol?

    The ticker symbol for Bausch + Lomb is BLCO.

  • What is the current stock price of Bausch + Lomb?

    As of 20-Nov-2026 the stock price of Bausch + Lomb is $19.30.

  • What is the current market cap of Bausch + Lomb?

    The current market capitalization of Bausch + Lomb is $6.9B.

  • What is Bausch + Lomb’s current revenue?

    The trailing twelve month revenue for Bausch + Lomb is $5.42B.

  • Who are Bausch + Lomb’s competitors?

    Alcon, The Cooper Companies, Staar Surgical, RxSight, and Novo Nordisk are some of the 8 competitors of Bausch + Lomb.

  • What is Bausch + Lomb’s annual earnings per share (EPS)?

    Bausch + Lomb’s EPS for 12 months was -$0.31.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process